Ubrelvy patent expiration?

When does the patent exclusivity period for Ubrelvy expire?

The patent for Ubrelvy (ubrogepant), a treatment for acute migraines, has various expiration dates depending on the country and the specific patent claims [1]. In the United States, the US Patent and Trademark Office (USPTO) has granted Novartis, the manufacturer of Ubrelvy, several patents covering the drug.

According to DrugPatentWatch.com, a website that tracks pharmaceutical patents [2], one of the key patents for Ubrelvy is expected to expire in 2028. However, this date may be delayed due to various factors, including extensions, re-filings, or patent challenges.

Can biosimilars enter the market before the patent expires?

While Ubrelvy's patent is still in force, regulatory actions can affect the market entry of biosimilars. Biosimilars are similar to biologic drugs, but their production is based on a biosimilar product. Manufacturers of biosimilars can file for regulatory approval before the patent expires, and in some cases, they can gain marketing exclusivities through separate patents or data exclusivities granted by regulatory agencies [3].

What happens after the patent expires?

When Ubrelvy's patent expires, other companies can manufacture and market generic versions of the drug. This is expected to increase competition in the market, potentially leading to lower prices for patients. However, generic versions of Ubrelvy would not have the same level of marketing support as the original product, which could impact their market share.

Sources:

[1] US Patent and Trademark Office: Patent search for "Ubrelvy"
[2] DrugPatentWatch.com: Ubrelvy (ubrogepant) patent information
[3] FDA.gov: Biosimilars: Biosimilar Approvals and Market Authorization Applications